The impact of diabetes mellitus and its control on the development of tuberculosis: A nationwide longitudinal study in Taiwan

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 9, 2013, Pages 995-1003

  Lee, Ming Chia ^a   Lee, Chih Hsin ^a,b,c   Shu, Chin Chung ^d   Pong, Wei Bang ^a   Lan, Chou Chin ^a,c   Wang, Jann Yuan ^d   Lee, Li Na ^d   Chao, Kun Mao ^b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Adherence; Cohort study; Diabetes mellitus; National Health Insurance Database; Pharmacoepidemiology; Tuberculosis

Indexed keywords

CORTICOSTEROID; INSULIN; ORAL ANTIDIABETIC AGENT; PRESCRIPTION DRUG; TUBERCULOSTATIC AGENT;

ADULT; AGE; AGED; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC PATIENT; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENDER; HOSPITAL ADMISSION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LIVER CIRRHOSIS; LONGITUDINAL STUDY; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; TAIWAN; TUBERCULOSIS; TUBERCULOSIS CONTROL;

EID: 84882603914     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3491     Document Type: Article

References (50)

1. WHO. Global Tuberculosis Control. WHO/HTM/TB/2011.393. Geneva: World Health Organization; 2011. Available online at http://www.who.int/tb/publications/global_report/2011/en/index.html (Accessed October 9, 2012).
2. Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300: 423-430.
3. Oeltmann JE, Kammerer JS, Pevzner ES, Moonan PK. Tuberculosis and substance abuse in the United States, 1997-2006. Arch Intern Med 2009; 169: 189-197.
4. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med 2008; 5: e152.
5. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006; 55: 19-26.
6. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
7. Tsukaguchi K, Okamura H, Ikuno M, et al. The relation between diabetes mellitus and IFN-gamma, IL-12 and IL-10 productions by CD4+ alpha beta T cells and monocytes in patients with pulmonary tuberculosis. Kekkaku 1997; 72: 617-622.
8. Stalenhoef JE, Alisjahbana B, Nelwan EJ, et al. The role of interferon-gamma in the increased tuberculosis risk in type 2 diabetes mellitus. Eur J Clin Microbiol Infect Dis 2008; 27: 97-103.
9. Martens GW, Arikan MC, Lee J, Ren F, Greiner D, Kornfeld H. Tuberculosis susceptibility of diabetic mice. Am J Respir Cell Mol Biol 2007; 37: 518-524.
10. Spatz M, Eibl N, Hink S, et al. Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. Cell Immunol 2003; 221: 15-26.
11. Leung CC, Lam TH, Chan WM, et al. Diabetic control and risk of tuberculosis: a cohort study. Am J Epidemiol 2008; 167: 1486-1494.
12. Wang JY, Lee LN, Lai HC, et al. Prediction of the tuberculosis reinfection proportion from the local incidence. J Infect Dis 2007; 196: 281-288.
13. Uys PW, van Helden PD, Hargrove JW. Tuberculosis re-infection rate as a proportion of total infection rate correlates with the logarithm of the incidence rate: a mathematical model. J Royal Soc Interface 2009; 6: 11-15.
14. Chang CH, Shau WY, Jiang YD, et al. Type 2 diabetes prevalence and incidence among adults in Taiwan during 1999-2004: a national health insurance data set study. Diabet Med 2010; 27: 636-643.
15. Lee CH, Lee MC, Lin HH, et al. Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease. PLoS One 2012; 7: e37978.
16. Luh K-T (ed.). Taiwan Guidelines for TB Diagnosis and Treatment (4th edn), Centers for Disease Control, R.O.C. (Taiwan): Taipei, Taiwan, 2011.
17. WHO. Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 14th ed; 2011.
18. Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009; 9: 737-746.
19. Dobler CC, Flack JR, Marks GB. Risk of tuberculosis among people with diabetes mellitus: an Australian nationwide cohort study. BMJ Open 2012; 2: e000666.
20. Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis 2012; 54: 818-825.
21. Coker R, McKee M, Atun R, et al. Risk factors for pulmonary tuberculosis in Russia: case-control study. BMJ 2006; 332: 85-87.
22. Shetty N, Shemko M, Vaz M, D'Souza G. An epidemiological evaluation of risk factors for tuberculosis in South India: a matched case control study. Int J Tuberc Lung Dis 2006; 10: 80-86.
23. Buskin SE, Gale JL, Weiss NS, Nolan CM. Tuberculosis risk factors in adults in King County, Washington, 1988 through 1990. Am J Public Health 1994; 84: 1750-1756.
24. Perez A, Brown HS, 3rd, Restrepo BI. Association between tuberculosis and diabetes in the Mexican border and non-border regions of Texas. Am J Trop Med Hyg 2006; 74: 604-611.
25. Ponce-De-Leon A, Garcia-Garcia Md Mde L, Garcia-Sancho MC, et al. Tuberculosis and diabetes in southern Mexico. Diabetes Care 2004; 27: 1584-1590.
26. Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997; 87: 574-579.
27. Kim SJ, Hong YP, Lew WJ, Yang SC, Lee EG. Incidence of pulmonary tuberculosis in Korean civil servants. Tuber Lung Dis 1995; 76: 534-539.
28. Restrepo BI, Fisher-Hoch SP, Pino PA, et al. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis 2008; 47: 634-641.
29. Al-Attiyah RJ, Mustafa AS. Mycobacterial antigen-induced T helper type 1 (Th1) and Th2 reactivity of peripheral blood mononuclear cells from diabetic and non-diabetic tuberculosis patients and Mycobacterium bovis bacilli Calmette-Guerin (BCG)-vaccinated healthy subjects. Clin Exp Immunol 2009; 158: 64-73.
30. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989; 321: 1074-1079.
31. Harvey JN. Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Curr Opin Nephrol Hypertens 2003; 12: 317-322.
32. Ayodele OE, Alebiosu CO, Salako BL. Diabetic nephropathy-a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc 2004; 96: 1445-1454.
33. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
34. Boucot KR, Dillon ES, Cooper DA, Meier P, Richardson R. Tuberculosis among diabetics: the Philadelphia survey. Am Rev Tuberc 1952; 65: 1-50.
35. Swai AB, McLarty DG, Mugusi F. Tuberculosis in diabetic patients in Tanzania. Trop Doct 1990; 20: 147-150.
36. Moss SE, Klein R, Klein BE. Risk factors for hospitalization in people with diabetes. Arch Intern Med 1999; 159: 2053-2057.
37. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med 2006; 355: 1903-1911.
38. Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE. Hyperglycemic crises in urban blacks. Arch Intern Med 1997; 157: 669-675.
39. Stead WW. Special problems in tuberculosis. Tuberculosis in the elderly and in residents of nursing homes, correctional facilities, long-term care hospitals, mental hospitals, shelters for the homeless, and jails. Clin Chest Med 1989; 10: 397-405.
40. Ramaswamy R, Corpuz M, Hewlett D. Tuberculosis surveillance of community hospital employees. A recommended strategy. Arch Intern Med 1995; 155: 1637-1639.
41. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011; 33: 74-109.
42. Adams AS, Trinacty CM, Zhang F, et al. Medication adherence and racial differences in A1C control. Diabetes Care 2008; 31: 916-921.
43. Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007; 100: 345-350.
44. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004; 27: 2800-2805.
45. Bloomgarden ZT. Inflammation and insulin resistance. Diabetes Care 2003; 26: 1922-1926.
46. Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis 1982; 125: 8-15.
47. Inghammar M, Ekbom A, Engstrom G, et al. COPD and the risk of tuberculosis-a population-based cohort study. PLoS One 2010; 5: e10138.
48. Lin HH, Ezzati M, Chang HY, Murray M. Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med 2009; 180: 475-480.
49. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555.
50. Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003; 16: 38-44.